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Abstract
Abdominal recurrences of renal cell carcinoma (RCC) after surgery might represent a challenge for treatment, often
requiring difficult surgeries or anticipated systemic therapy. Our aim is to illustrate a novel application of laser
ablation for the treatment of abdominal recurrences of RCC. Patients with abdominal recurrences of renal cancer
were treated under ultrasound/computed tomography guidance with a diode laser inserted into the lesion through
a thin 21-G needle. A fixed 3-W power protocol was used, changing the illumination time according to lesion
dimension and shape. Also, technical success, technical efficacy, local tumour progression, and major and minor
complications were retrospectively analysed. Three patients were treated with image-guided laser ablation for
abdominal recurrences of RCC. In all cases, it was possible to perform ablation as preoperatively planned and all
three nodules (size of 6, 8, and 12 mm) were completely ablated with no evidence of residual enhancement after 6
weeks at contrast-enhanced CT. No minor or major complications were observed. No local tumour progression was
reported up to 12 months from ablation. Image-guided laser ablation holds the potential to offer a minimally
invasive treatment to patients with abdominal recurrence of RCC. Further studies are needed to evaluate the clinical
role of this technique.
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Key points
 Three patients with abdominal recurrence of renal
tumours underwent image-guided laser ablation.
 All three treatments were successful, without any
complications.
 No local tumour progression was reported up to 12
months from ablation.
 Difficult reoperation could be avoided and systemic
therapy could be postponed by successful laser
ablation of abdominal recurrences of renal tumours.
Background
Renal cell carcinoma (RCC) is a common urologic malig-
nant lesion in adults and accounts for 2.6% of all cancers
[1]. It may occur at any age, although most patients are
older than 40 years, and people in the seventh and eighth
decades of life are most commonly affected. Other risk
factors are smoking, obesity, and hypertension [2].
Surgery, in the form of radical or partial nephrectomy,
is still considered the first choice of treatment for RCC
[3], while image-guided thermal ablation is rapidly emer-
ging as an effective alternative, with similar results, lower
complications and lower costs [4–7]. However, while
most of the patients benefit from these treatments and
remain disease-free for years, approximately 2–4% of
cases can relapse [8]. Treatment options are limited for
locally recurrent RCC, and there are currently no
consensus treatment protocols.
Image-guided thermal ablations have been proposed
also for the treatment of recurring lesions with the aim
of achieving an accurate and precise eradication of the
target tumour with a reduced invasiveness. Some studies
in limited numbers of patients have reported promising
results with radiofrequency ablation (RFA) of local
relapses of RCC [9–11].
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Laser ablation is the ablative method with the smallest
applicator among various ablative techniques and, for
this reason, has been proposed as a theoretically ideal
ablative modality for the treatment of small lesions in
difficult locations [12–15]. Thus, we developed a novel
treatment strategy, implying ultrasound and CT guid-
ance for the application of laser ablation to abdominal
recurrences of RCC, in order to minimise the invasive-
ness of the treatment.
The aim of the present paper is to illustrate our treat-
ment technique of laser ablation for the treatment of re-
currences after renal surgery in patients treated for RCC.
Patients and technique
All cases were discussed in our multi-disciplinary team,
composed of one urologist, one oncologist, and one inter-
ventional radiologist. Image-guided thermal ablation was
proposed as the best treatment option by consensus. All
patients were visited by one interventional radiologist in
the outpatient consultation room, and a full explanation
of the procedure was given with particular attention to the
pros and cons. Thus, a formal written informed consent
was obtained. Patients also provided written informed
consent for the use of clinical data for research purposes.
The internal institutional review board approved the
retrospective study. A week before the treatment, all
patients were referred to our preliminary assessment service
for a complete check of their general clinical condition by
an anaesthesiologist.
Patients’ characteristics, staging for the primary lesion,
and type of primary treatment are reported in Table 1.
Image-guided laser ablations were performed in a ded-
icated operatory room equipped with CT and ultrasound
machines, under general anaesthesia. Patients were posi-
tioned choosing the most favourable path for a direct
needle approach to the lesions [4]. Also, CT and ultra-
sound real-time fusion imaging was available and applied
during the procedure [4]. A preliminary CT was per-
formed with the patient in the chosen position, and the
CT dataset was used for fusion with real-time ultra-
sound. Then, a 21-G needle was inserted under ultra-
sound monitoring at the level of the lesion to be treated,
and its correct position confirmed by an unenhanced
CT acquisition. If needed, hydrodissection through the
injection of sterile water was also performed before abla-
tion in order to protect adjacent structures from heat
damage [4]. Then, a 0.3-mm laser fibre was inserted into
the 21-G needle and thermal ablation performed with a
commercially available semi-conductor diode laser sys-
tem with a wavelength of 1064 nm (Echolaser, Elesta Srl,
Florence, Italy). A fixed 3-W power protocol was used
with a total energy delivered of 1,200–1,800 J for a single
illumination. At the end of the procedure, a triple-phase
contrast-enhanced CT scan (acquisition of arterial, ven-
ous and late phase, with an injection rate of 3.5 mL/s)
was performed to evaluate the immediate result of abla-
tion and to look for immediate complications. All pro-
cedures were performed by two of four interventional
radiologists, all with more than 5 years of experience in
thermal ablation procedures.
All procedures were performed in the Interventional
Radiology department under general anaesthesia (per-
formed following usual protocols); in all cases, it was
possible to perform ablation as preoperatively planned.
No minor or major complications were detected. After
laser ablation, all patients were observed overnight and
discharged the following day. All three nodules were
completely ablated with no evidence of residual en-
hancement in contrast-enhanced CT examinations at
the 6 weeks (100% technical success). Contrast-enhanced
CT performed at 12 months showed complete ablation
with no local tumour progression. All contrast-enhanced
CT scans were acquired using triple-phase protocols,
according to usual practice.
A case of a patient with an 8-mm recurrence located
in renal fossa is presented in Fig. 1. Table 2 reports
characteristics of the recurrent lesions (number, size,
location, timing), details of the procedure and of the
immediate postoperative period (time, energy used,
need of hydrodissection, hospital days, complication),
and results of follow-ups.
Discussion
We retrospectively reviewed the cases of three male
patients affected with abdominal recurrent RCC treated
with laser ablation. We included all patients who, after
Table 1 Patients’ characteristics
Patients
1 2 3
Age 42 69 73
Sex M M M
Tumour histopatology RCC RCC RCC
Staging pT1b pNx pT3a pN0 pT1 pNx
Surgical treatment Radical nephrectomy Radical nephrectomy Enucleoresection
RCC Renal cell carcinoma
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undergoing previous treatments for RCC (surgery or
image-guided thermal ablation), had a local recurrence
of disease with lesions smaller than 2 cm and no other
metastatic site elsewhere after staging with a contrast-
enhanced CT scan.
Recurrences of RCC after surgical treatment are rare
but, when they occur, are associated with a negative prog-
nosis; although surgery remains the gold standard, reinter-
vention not only increases morbidity for the patient but is
also not always feasible. Some patients may not undergo
surgery because of advanced age, end-stage renal disease,
and other comorbidities. Furthermore, postoperative
fibrosis, altered anatomy from prior surgery, and recurrent
disease adjacent to retroperitoneal structures can cause
anatomical limitations that make complex a complete
resection of the recurrence lesion [16, 17].
Percutaneous ablative therapies, thanks to the use of
an image-guided approach and their minimally invasive
nature, could bypass these limits and could represent an
effective and less invasive therapeutic strategy in patients
with recurrent RCC. However, experiences reporting
image-guided thermal ablation of recurrent RCCs are
still limited [9–11] and deal mainly with the use of RFA.
The first case was reported in 2002 by McLaughlin et al.
[10]. They described the use of percutaneous RFA after rad-
ical nephrectomy for a patient with recurrent disease con-
sidered non-resectable due to the close proximity to the
abdominal aorta. The intervention was successful and with-
out any complications; the patient remained disease-free
for the next 16months of follow-up. The safety and onco-
logical efficacy of this procedure were further proved by
Monfardini et al. [9], with their eight patients who were
treated with percutaneous RFA for local recurrence after
surgery (radical or partial nephrectomy). No complication
was reported, and all nodules (mean size = 1.6 cm) were
completely ablated. After the procedure, for a mean follow-
up of 12months, no residual disease has been observed.
Recently, Zhou et al. [11] have studied a cohort of 11
patients with local RCC relapses with mean size of 2.8
cm treated using RFA, cryoablation, or, in one case, mi-
crowaves. Technical success was achieved in 100% of the
cases without major complications. The results have also
been promising from an oncological perspective. In all
cases, except one, a complete response has been
obtained according to RECIST criteria [18], with a local
progression-free during the mean follow-up time of 2.5
years. Thus, so far, no established technique has been
fully validated for the treatment of recurrent RCC.
Fig. 1 Forty-two-year-old male patient with small left recurrence of renal cell carcinoma. a Contrast-enhanced computed tomography (CT) scan
before treatment. A pathological nodule of 8 mm is clearly visualised in the left kidney fossa (white arrow). b Unenhanced CT scan with the
patient placed in a prone position. Laser ablation procedure: the needle of the laser device is clearly seen placed insight the pathological nodule
during the treatment (white arrow). c Contrast-enhanced CT scan after treatment. The small pathological nodule does not show any contrast
uptake demonstrating the effectiveness of the treatment (white arrow)
Table 2 Details of recurrent tumour, procedure, and follow-up
Patients
1 2 3
Time to recurrence (months) 49 72 30
Lesion number 1 1 1
Tumour recurrence size (mm) 8 12 6
Tumour recurrence location Renal fossa Perisplenic Adrenal loggia
Procedure time (min) 70 65 46
Energy used (J) 1,800 1,800 1,200
Hydrodissection Yes No No
Hospital stay (days) 2 2 2
Complications None None None
Follow-up (CT at < 2 days) Negative Negative Negative
Follow-up (CT at 6 weeks) Negative Negative Negative
Follow-up (CT at 6 months) Negative Negative Negative
CT Computed tomography
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At our department, we decided to treat small recurrent
RCC (size 6, 8, and 12mm) with a laser ablation in order
to minimise the treatment invasiveness. Laser technology
is based on the precise focal application of a laser light
through a small optic fibre to achieve a local temperature
increase and cell coagulative necrosis [19]. The application
through such small applicators is possible thanks to two
distinctive features of the laser light beam: collimation and
monocromaticity. Accurate image guidance is crucial for a
precise and effective thermal ablation, and particularly, the
availability of both ultrasound and CT guidance methods,
with also the possibility of performing fusion imaging and
virtual navigation, might increase the result of ablation of
recurrences of RCC, which are often of small dimension
and located in difficult anatomical positions [20, 21].
In our small series, laser ablation was proven to be fea-
sible and safe in the treatment of patients with recurrent
RCCs, without complications, and with excellent recovery
times (see Table 2). To the best of our knowledge, this
paper represents the first description of the application of
laser ablation to recurrent RCC.
In conclusion, this study, despite the limitations,
underlines the feasibility and the potential curative role
of laser ablation for small isolated RCC local recurrence
after surgery. Such treatment option holds the potential
to offer a minimally invasive effective treatment to
patients with recurrence after RCC surgical resection.
Larger studies with longer follow-up are needed to
confirm these preliminary results, possibly comparing
laser ablation to surgical re-interventions or other
thermal ablation modes.
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